ACQUISITIONS AND TRANSACTIONS (Details)	1 Months Ended	3 Months Ended		6 Months Ended			3 Months Ended		6 Months Ended	12 Months Ended						3 Months Ended		12 Months Ended
	May 31, 2011 USD ($)	Jun. 30, 2011 USD ($)	Jun. 30, 2010 USD ($)	Jun. 30, 2011 USD ($)	Jun. 30, 2010 USD ($)	May 02, 2011 Teva Pharmaceutical Industries Ltd. USD ($)	Jun. 30, 2011 ChemGenex Pharmaceuticals Limited USD ($)	Mar. 31, 2011 ChemGenex Pharmaceuticals Limited USD ($)	Jun. 30, 2011 ChemGenex Pharmaceuticals Limited USD ($)	Dec. 31, 2010 ChemGenex Pharmaceuticals Limited USD ($)	Dec. 31, 2010 ChemGenex Pharmaceuticals Limited AUD	Jul. 21, 2011 ChemGenex Pharmaceuticals Limited	Jun. 30, 2011 ChemGenex Pharmaceuticals Limited AUD	Jun. 06, 2011 ChemGenex Pharmaceuticals Limited USD ($)	Apr. 30, 2011 ChemGenex Pharmaceuticals Limited AUD	Jun. 30, 2011 Gemin X Pharmaceuticals USD ($)	Jun. 30, 2011 Gemin X Pharmaceuticals USD ($)	Dec. 31, 2010 Gemin X Pharmaceuticals USD ($)	Apr. 30, 2011 Gemin X Pharmaceuticals USD ($)	Apr. 18, 2011 Gemin X Pharmaceuticals USD ($)
Acquisitions and transactions
Common Stock Merger Agreement Price Per Share	$ 81.50							$ 0.64
Cash to be received for each share of the entity's common stock under the Merger Agreement (in dollars per share)						$ 81.50
Termination fee to be paid if the Merger Agreement is terminated by the Company						$ 275,000,000
Payment for convertible notes under a convertible note subscription agreement											15,000,000
Conversion price per share of stock under a convertible note subscription agreement											0.5
Minimum number of tyrosine kinase inhibitor (TKIs) failed by CML patients to use OMAPRO under a New Drug Application submission										2	2
Number of major ChemGenex shareholders with which option agreements were entered into by the entity										2	2
Maximum percentage of additional outstanding shares which the entity has the right to acquire under the option agreements (as a percent)										19.90%	19.90%
Price per share to acquire additional outstanding shares under the option agreements (in Australian dollars per share)											0.7
Exercise period to acquire additional outstanding shares under the option agreements (in days)										10	10
Convertible notes										9,900,000
Purchase option assets										900,000
Cash offered per share for each ChemGenex Share, cum dividend rights (in Australian dollars per share)															0.70
Cash offered per share for each ASX listed ChemGenex Option (in Australian dollars per share)															0.02
Percentage of minimum acceptance condition under the offer terms (as a percent)															90.00%
Equity interest held (as a percent)												100.00%	93.40%
Equity interest acquired (as a percent)														90.60%
Price paid per share (in AUD per share)													0.70
Funds used to acquire acquiree entity's shares, net of foreign exchange contracts									164,600,000
Payments to acquire interest in subsidiaries and affiliates subsequent to current period									14,900,000
Payment for acquisition of equity interest								40,600,000
Consideration paid for cumulative interest in acquiree entity, including the convertible note and purchase option								220,000,000
Gains on foreign exchange contracts resulting from compulsory acquisition									5,600,000
Percentage of equity interest acquired (as a percent)								27.60%					27.60%	27.60%
Fair value of equity interest acquired								56,700,000						64,900,000
Changes in fair value of investments		99,473,000		264,208,000				8,300,000
Operating expenses										16,000,000								13,500,000
Net losses related to acquired entity		(118,175,000)	(89,064,000)	(329,263,000)	(199,629,000)		2,500,000		2,500,000								3,000,000
Gain (loss) from the increase (decrease) in fair value of foreign exchange contracts		5,595,000	(2,900,000)	5,089,000	(9,069,000)		5,600,000		5,600,000
Cash paid to acquire all of the outstanding capital stock																			225,000,000
Cash consideration net of cash, debt and transaction costs																			190,000,000
Cash payments to be made upon the achievement of certain regulatory and sales milestones																			300,000,000
Fair value of the consideration transferred to acquire an entity																			287,100,000
Undiscounted amount of potential milestone payments due in upcoming years, low end of range																0	0
Undiscounted amount of potential milestone payments due in upcoming years, high end of range																300,000,000	300,000,000
Fair value of the liability for the contingent consideration recognized on the acquisition date																			97,100,000
Changes in the fair value of contingent consideration liability																900,000
Fair value of contingent consideration liability																98,000,000	98,000,000
Carrying amounts and classification of acquiree entity's assets and liabilities included in consolidated balance sheet
Cash and cash equivalents														11,114,000						5,828,000
Accounts receivable																				248,000
Other current assets														239,000						196,000
Property and equipment, net														153,000						722,000
Goodwill														393,000						3,970,000
Intangible assets														230,700,000						333,300,000
Deferred tax assets														3,007,000						2,276,000
Current portion of long-term debt																				836,000
Accounts payable														3,950,000
Accrued expenses														5,989,000						7,743,000
Deferred tax liabilities, net																				17,299,000
Long-term debt																				33,526,000
Noncontrolling interest														$ 22,075,000